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Summary
Objectives: Serum deoxyribonuclease I (DNase I) activity has recently been high-
lighted as a potential diagnostic marker for the early detection of an acuteDNase I; myocardial infarction (AMI). We evaluated whether the serum DNase I activity was
ameters of the left ventricular (LV) remodeling after an AMI.Left ventricular associated with the parremodeling Methods: We measured the serum DNase I activity in 45 patients with an AMI who
were admitted to our hospital within approximately 4 h of the onset of their chest
pain. We also evaluated the LV ejection fraction (LVEF), LV end-diastolic volume
(LVEDV), and LV end-systolic volume (LVESV) of each patient by echocardiography at
the time of admission and at 6 months after the onset of the AMI.
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Results: The serum DNase I activity peaked at 3.5± 2.0 h after the onset of the symp-
toms in the patients with an AMI, thereafter exhibiting a time-dependent decline
within 12 h, and a return to the basal level within 24 h in almost all cases. Neither the
LVEF, LVEDV, nor LVESV in each patient on admission exhibited a signiﬁcant correlation
to the peak levels of the serum DNase I activity. Although there was no correlation
between the peak DNase I activity and LVEF at 6 months after the onset, a signiﬁ-
cant positive correlation of the peak DNase I activity with LVEDV and LVESV (r = 0.48,
p < 0.001 and r = 0.34, p = 0.02, respectively) was found.
Furthermore, the LVEDV at 6 months after the onset in the high DNase I activity group
(>17.9U/L) were signiﬁcantly higher than those in the low DNase I activity group
(≤17.9 U/L) (118.0± 28.2ml vs 89.3± 25.4ml, p = 0.026).
Conclusions: The serum DNase I activity level may predict LV enlargement associated
with remodeling after an AMI.
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criteria [8].
The study protocol conformed to the Declaration© 2008 Japanese Colleg
reserved.
ntroduction
eft ventricular (LV) remodeling after an acute
yocardial infarction (AMI) is the process of an
nfarct expansion followed by progressive dila-
ion of the entire LV including the non-infarct
yocardium, and is a major predictor of morbidity
nd mortality [1]. Although the precise molecular
echanisms of the LV remodeling are still unknown,
poptosis in the non-infarcted remote myocardium
ppears to be involved [2]. However, no associa-
ion of any apoptosis-related biomarkers with LV
emodeling has been elucidated.
Deoxyribonuclease I (DNase I, EC 3.1.21.1) is an
ndonuclease that preferentially attacks double-
tranded DNA in a Ca2+-dependent manner to
roduce oligonucleotides with 5′-phospho and 3′-
ydroxy termini [3]. DNase I has been postulated
o be one of the candidate nucleases that are
esponsible for internucleosomal DNA degradation
uring apoptosis [4,5]. In this context, it has been
eported that the activity level of DNase I present
n human myocardium is elevated in heart failure
ue to idiopathic dilated cardiomyopathy [6]. Our
revious study demonstrated that the serum level
f DNase I activity was abruptly elevated within
pproximately 3 h after the onset of symptoms,
hereafter exhibiting a marked time-dependent
ecline within 12 h, and a return to the basal level
ithin 24 h [7], and that because the peak serum
evel of the DNase I activity after the AMI onset
as usually found within 4 h after the AMI onset
t the latest, it might become a cardiac marker
or diagnosing a superacute phase of an AMI [7].
owever, no study has ever been performed to
xamine the relationship between the levels of
he serum DNase I activity and LV function after
MI. Accordingly, in this study, we investigated
hether the peak levels of serum DNase I activ-
o
C
i
sCardiology. Published by Elsevier Ireland Ltd. All rights
ty after the onset of AMI could be associated with
he parameters of LV remodeling, such as the LV
jection fraction (LVEF), LV end-diastolic volume
LVEDV), and LV end-systolic volume (LVESV), in
he acute and chronic phases of an AMI, and also
ompared the results with those of creatine kinase
CK).
ethods
tudy population
ne hundred and ﬁfty-eight consecutive Japanese
atients with suspected AMI were admitted to our
ospitals between August 2004 and August 2006.
onsidering the characteristics of the changes in
he level of the serum DNase I activity after the
MI onset as described above [7], 93 patients
ith an AMI who were admitted to our hospital
t more than 4 h after the symptom onset of the
MI were excluded from this study beforehand.
mong the remaining 65 patients, 6 and 5 patients
ere excluded for inadequate echocardiographic
mage and old myocardial infarction, respec-
ively, from the study. Furthermore, 9 patients
eclined to take part in this study, and ulti-
ately 45 patients were enrolled. All of the study
atients received emergent coronary angiogra-
hy (CAG) and successful reperfusion therapy by
rimary coronary intervention (PCI) with stent-
ng. The clinical diagnosis of an AMI was made
ccording to the European Society of Cardiol-f Helsinki and was approved by the Human Ethics
ommittee of our institution; each subject included
n the study gave written informed consent before
tudy participation.
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Echocardiography
All patients underwent two-dimensional echocar-
diography at the time of admission and 6 months
after the onset of the AMI (Sonos 5500, Phillips
Medical Systems, MA, USA). A standard imaging
protocol was used based on the apical 4-chamber,
2-chamber, parasternal long- and short-axis views.
These images were recorded and analyzed by two
experienced blinded ultrasonographers. The LVEDV
and LVESV were calculated by the modiﬁed Simp-
son’s biplanemethod. The LVEF was calculated from
the formula (LVEDV− LVESV)× 100%/LVEDV. These
values were considered indicators of the magnitude
of the LV remodeling.
Collection of blood samples and the
measurement of the serum DNase I activity
and CK levels
Blood samples were obtained from an antecubital
vein at the time of admission, and every 3 h until
the peak CK levels were determined. Furthermore,
follow-up blood samples were obtained at 2, 3, 7,
and 14 days, and 6 months after the onset of the
AMI. The serum samples were prepared from each
blood sample by centrifugation and stored at−80 ◦C
until use.
Table 1 Clinical characteristics of the study
patients.
AMI patients
Total population 45
Age (years) 67 ± 11
Men 32 (71)
Coronary risk factor
Cigarette smoking 20 (44)
Diabetes mellitus 16 (36)
Hypertension 28 (62)
Hypercholesterolemia 31 (52)
Obesity 10 (22)
Culprit lesions
Left anterior descending 25 (56)
Left circumﬂex 9 (20)
Right coronary artery 11 (24)
STEMI 41 (91)
In-hospital medications
ACEIs or ARBs 36 (80)
-Blockers 14 (31)
Calcium antagonists 16 (36)
Diuretics 9 (20)
Data are presented asmean ± S.D. or number (%) of patients;
STEMI, ST elevatedmyocardial infarction; ACEIs, angiotensin-
converting enzyme inhibitors; ARBs, angiotensin-II receptor
antagonists.
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The DNase I activity levels in the serum samples
ere measured by a single radial enzyme diffu-
ion (SRED) method, as described previously [9,10].
ne unit of the enzyme assayed corresponded to
.6 ng of puriﬁed human DNase I [3]. The serum CK
oncentration was determined with an automated
hemiluminescence system (Ciba Corning Diagnos-
ics Corp., Medﬁeld, MA, USA), in accordance with
he manufacturer’s instructions.
tatistical analysis
ontinuous variables are expressed as the mean± 1
tandard deviation and the Student’s t-test was
sed to compare the 2 groups. The Spearman’s
orrelation coefﬁcient was used to determine the
elation between the peak DNase I, CK levels,
nd the echocardiographic parameters. Parameters
ere analyzed by parametric or non-parametric
ethod with or without normality of distributions.
data analysis was performed with StatView soft-
are, version 5.0 (Abacus Concept, Inc., Berkley,
A, USA). A p-value <0.05 was considered statisti-
ally signiﬁcant.
esults
atient characteristics
he clinical characteristics of studied patients are
hown in Table 1. There were 32 men and 13
omen, and their mean age was 67± 11 years.
he average time between the onset of symptoms
nd the hospital admission was 2.1± 1.2 h (range
.2—3.9). Twenty-eight (62%) of the patients had
ypertension, 31 (69%) hyperlipidemia, 16 (36%)
iabetes mellitus, and 20 (44%) were current smok-
rs. There were 4 patients with non-ST-elevation
I. None had any major adverse cardiac events,
eﬁned as a cardiac death, nonfatal AMI, or hos-
italization due to heart failure, during a mean
ollow-up period of 7.0± 0.6 months.
All patients were administered aspirin and ticlo-
idine after the PCI. Thirty-six patients (80%)
ere treated with angiotensin-converting enzyme
nhibitors (ACEIs) or angiotensin-II receptor antag-
nists (ARBs), whereas 14 patients (31%) were
reated with -blockers, and 16 (36%) were treated
ith calcium antagonists. Diuretics were used in 9
atients (20%) with congestive heart failure (CHF).lterations in the serum DNase I activity
evels following an AMI
he changes in the serum DNase I activity levels
rom the onset in patients with an AMI are shown
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eigure 1 Changes in the serum DNase I activity level as
MI admitted to our hospital within 4 h.
n Fig. 1. The serum DNase I activity level peaked
ithin 6 h after the onset of the symptoms in the
atients with an AMI, thereafter showing a time-
ependent decline within 12 h, and a return to the
asal level within 24 h in almost all cases, conﬁrm-
ng an alteration in serum DNase I activity levels of
he patients after the onset reported previously [7].
t
T
n
>
igure 2 Correlation between the peak serum DNase I activ
nd-diastolic volume (LVEDV; B), and end-systolic volume (LVEction of time from the onset in tens of patients with an
The peak level of serum DNase I activity was
4.7± 5.6U/L (range 6.9—25.7). The mean time
rom the onset of the symptoms to the peak level of
he DNase I activity was 3.5± 2.0 h (range 0.2—6.0).
he serum DNase I activity level exceeded the
ormal range, which was deﬁned as a value
17.9U/L [7] or the percent differences in the
ity level and left ventricular ejection fraction (LVEF; A),
SV; C) measured 6 months after the AMI.
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Figure 3 Correlation between the peak serum creatine kina
A), end-diastolic volume (LVEDV; B), and end-systolic volume
serum DNase I activity at 3 h after the admission
was >12.4% [11] in 33 (73%) patients. The peak
level of the serum DNase I activity did not differ
between the patients with and without hyperten-
sion (p = 0.62), hyperlipidemia (p = 0.11), diabetes
mellitus (p = 0.75), or a current smoking habit
(p = 0.82).
Figure 4 Comparison of the LVEDV 6 months after the
AMI between the high DNase I group and the low DNase I
group.
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pse (CK) and and left ventricular ejection fraction (LVEF;
(LVESV; C) measured 6 months after the AMI.
elationship of the peak serum DNase I
ctivity and CK levels with the
chocardiographic parameters
he peak serum DNase I activity levels in patients
as not correlated with LVEF, LVEDV, and LVESV
n admission, and furthermore with the LVEF mea-
ured at 6 months after the AMI (Fig. 2A). However,
igniﬁcant correlations of the peak serum DNase I
ctivity levels with the LVEDV (r = 0.48, p < 0.001)
nd LVESV (r = 0.34, p = 0.02) measured at 6 months
fter the AMI were found in a positive manner
Fig. 2B and C).
There was no signiﬁcant difference found in the
eak serum DNase I activity level and peak serum
K (r = 0.11, p = 0.49) levels.
The peak serum CK (r =−0.60, p < 0.001, Fig. 3A)
evels were signiﬁcantly correlated with the LVEF
months after the onset in a negative manner,
hereas they were correlated with the LVESV 6
onths after the AMI in a positive manner (r = 0.45,
= 0.002, Fig. 3C). However, there was no signif-
cant correlation between the peak CK level and
VEDV measured 6 months after the AMI (r = 0.23,
= 0.12, Fig. 3B).
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deoxyribonuclease I activity predicts left ventricula
Next, we divided these patients into a high DNase
activity group whose peak DNase I activity was
bove 17.9U/L and a low DNase I activity group
hose activity was less than 17.9U/L according to
he previous report [7]. The LVEDV at 6 months after
he AMI in the high DNase I activity group was signif-
cantly higher than those in the low DNase I activity
roup (118.0± 28.2ml vs 89.3± 25.4ml, p = 0.026,
ig. 4). However, both LVESV and LVEF at 6 months
fter the AMI did not differ between the two groups.
iscussion
ajor ﬁndings
n this clinical study, we conﬁrmed that the peak
evels of serum DNase I activity were observed at
.5± 2.0 h after the onset of chest pain and exhib-
ted a time-dependent decline, and returned to a
ormal level within about 24 h, which was consis-
ent with our previous report [7]. Examination of
he correlation between the peak serum DNase I
ctivity levels on admission and echocardiographic
arameters of the LV remodeling permitted us to
emonstrate that the peak DNase I levels were sig-
iﬁcantly correlated with the LVEDV and LVESV 6
onths after the onset of an AMI in a positive man-
er. However, there was no correlation between the
eak DNase I activity level and the LVEF after 6
onths. Furthermore, we found that the LVEDV at 6
onths after the AMI was signiﬁcantly higher in the
igh DNase I group than in the low DNase I group.
These ﬁndings may indicate that the peak levels
f the serum DNase I activity can be a predictor of
V enlargement, but not of the LV function after an
MI; the higher the peak levels are, the larger the
V end-diastolic and end-systolic volumes are.
erum DNase I activity levels in AMI patients
he treatment with the PCI procedures made the
erum CK levels become elevated in the patients
ith an AMI, whereas the serum DNase I did not.
hese ﬁndings allowed us to clarify that the serum
Nase I activity level did not become affected by
he PCI procedure in a different manner than that
or the CK in the AMI-patients. According to a num-
er of previous reports, DNase I is secreted by
xocrine glands, such as the pancreas and parotid
land, into the alimentary tract [12—14]. Further-
ore, DNase I has also been detected in various
issues, including the small intestine, stomach, kid-
ey, heart, liver, and pituitary gland, in which the
Nase I is stored in the secretory granules of the
w
b
t
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ells and secreted into the lumen [15,16]. It is
lausible to suggest that DNase I may be secreted
rom granules in the myocardium as well as brain
atriuretic peptide, when triggered by myocar-
ial ischemia, and may take time until it can be
tored in the granules after its secretion. There-
ore, the DNase I might not exhibit an elevated
erum level after the PCI procedure in patients
ith an AMI. In this study, 12 patients did not
xhibit any distinct alterations in the serum DNase
activity levels irrespective of whether or not it
as early after the onset of the AMI. Recently, we
emonstrated that the serum DNase I activity level
ould be a marker of transient myocardial ischemia
fter PCI and vasospastic angina pectoris [10,17].
ccordingly, it is plausible that the DNase I did not
ecome elevated in those patients because of the
ransient myocardial ischemia induced by the pro-
romal angina before the onset of the AMI. Further
tudy will be needed to elucidate the effect of the
rodromal angina on the DNase I levels in patients
ith an AMI.
eak serum DNase I activity level as a
arker for LV enlargement
he progressive LV enlargement was associated
ith an increased incidence of morbidity and mor-
ality after the AMI [1]. Although the precise
olecular mechanisms of the LV remodeling are still
nknown, myocyte apoptosis in the non-infarcted
emote myocardium appears to be involved [2].
Nase I has been postulated to be one of the
andidate nucleases that are responsible for the
nternucleosomal DNA degradation during apopto-
is [4,5]. Recently, we reported that the serum
Nase I activity level became elevated transiently
nd abruptly after the onset of an AMI [7]. Oliveri
t al. [18,19] reported that DNase I is internal-
zed by human cells upon binding with mannose
-phosphate receptors and behaves as a transcrip-
ional factor which modulates the Fas expression
eading to the induction of apoptosis. Most of the
ell death in the ﬁrst 2—4 h following a coronary
cclusion has been known to occur by apoptosis
rom rat myocardial infarction models [20—22]. On
he basis of these ﬁndings, we postulated that
he serum DNase I may induce myocardial apopto-
is followed by LV remodeling. This clinical study
emonstrated that the peak DNase I activity level
as positively associated with the LVEDV and LVESV,
ut not with the LVEF, 6 months after the onset of
he AMI, whereas the peak CK levels were signiﬁ-
antly associated with the LVEF after 6 months in
negative manner. On the other hand, the peak
(
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DNase I activity level did not correlate with the
CK levels which are used in assessing the cellular
necrosis and reﬂect the infarct size after an AMI.
Therefore, these ﬁndings that the DNase I did not
reﬂect the infarct size, but were associated with
the LV dilation during the chronic phase permitted
us to speculate that the peak DNase I activity lev-
els in the acute phase of an AMI may predict the LV
enlargement unlike the CK level.
Limitations
First, our sample size was small. However, the
results of this study will facilitate further stud-
ies using larger numbers of patients to evaluate
whether the serum DNase I activity level is a
predictive marker for LV remodeling. Secondly, it
remains to be clariﬁed how myocardial ischemia
induced by an AMI could elevate the levels of the
serum DNase I activity in the patients. It has been
demonstrated that both the level of the DNase I
activity and DNase I gene expression in cultured
human cells increases under hypoxia in compari-
son with normoxia, suggesting that hypoxia allows
the serum DNase I activity to rise, perhaps due to
up-regulation of the DNase I gene [23,24]. Hypoxia-
induced up-regulation of the gene expression can
partly account for how the levels of the DNase I
activity in the serum of the patients are elevated in
response to ischemia. However, further clariﬁcation
of the mechanism responsible for the DNase I eleva-
tion and physiological signiﬁcance of the DNase I in
myocardial ischemia will undoubtedly have impor-
tant biological and clinical implications. Finally, the
LV remodeling after an AMI is affected by the early
reperfusion and drug treatment [25—28]. All the
patients in this study underwent a successful PCI
within 6 h after the onset of the AMI and 36 patients
(80%) were treated with ACEIs or ARBs which pre-
vent LV remodeling. Therefore, we consider that
these factors did not affect the association between
the peak DNase I activity and LVEDV and LVESV.
Conclusions
The serum DNase I activity level may predict the LV
enlargement and may be a potential tool for risk
stratiﬁcation after an AMI.Acknowledgments
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